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Abstract
Twenty-eight compounds related to dehydrozingerone (1), isoeugenol (3), and 2-hydroxychalcone
(4) were synthesized and evaluated in vitro against human tumor cell replication. Except for
isoeugenol analogs 27−35, most compounds exhibited moderate or strong cytotoxic activity against
KB, KB-VCR (a multi-drug resistant derivative), and A549 cell lines. In particular, chalcone 15
showed significant cytotoxic activity against the A549 cell line with an IC50 value of 0.6 μg/mL.
Furthermore, dehydrozingerone analog 11 and chalcones 16 and 17 showed significant and similar
cytotoxic activity against both KB (IC50 values of 2.0, 1.0, and 2.0 μg/mL, respectively) and KB-
VCR (IC50 values of 1.9, 1.0, and 2.0 μg/mL, respectively) cells, suggesting that they are not
substrates for the p-glycoprotein drug efflux pump.
Dehydrozingerone (1), isolated from ginger (Zingiber officinale),1,2 is a well known phenolic
natural product with anti-inflammatory, antioxidant, and antitumor promoting activities.3 It is
the structural half analog, as well as biosynthetic intermediate,4 of curcumin (2), which
possesses various remarkable bioactivities such as cytotoxic effects on cancer cell lines5-8 and
induction of apoptotic cell death in human promyelocytic leukemia HL-60 and human oral
squamous carcinoma HSC-4 cells.9 Dehydrozingerone (1), isoeugenol (3) and 2-
hydroxychalcone (4) (Figure 1) have similar structures (acetyl, methyl and benzoyl,
respectively, attached to a styrene skeleton). Both 3 and 4 are also prominent bioactive
compounds.10,11 Thus, we expected that 1-analogs should show a wide range of
pharmacological activities. In spite of the interesting and simple structure of 1, we found only
a few literature reports on analog syntheses and structure-activity relationships (SAR),12,13
although we recently reported the cytotoxic effects of curcumin analogs.7,14,15
It is known that the presence of a prenyl or geranyl group on flavonoids, including chalcones,
can lead to a remarkable increase in bioactivity.16,17 As dehydrozingerone (1) is structurally
related to chalcones, the introduction of a prenyl or geranyl group on any position of 1 might
also increase activity. In fact, most prenylflavonoids and geranylflavonoids as well as related
compounds are known to have potent cytotoxic effects.18-21 Furthermore, with respect to
cancer research, a prenyl moiety has been demonstrated to be essential for chemopreventive
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activity in many compound types.22-24 Therefore, we herein report the syntheses and cytotoxic
activities of dehydrozingerone analogs, including investigation of prenyl substitution.
Results and Discussion
As shown in Scheme 1, dehydrozingerone (6−13) and chalcone (14−17) analogs with various
substitution patterns on the benzylidene ring were easily obtained from substituted
benzaldehydes (5) reacted with the appropriate ketone (acetone for 6−13, acetophenone for 14
−17) using an aldol condensation.12 Alkylation/allylation of the phenol of 1 or 3 was achieved
by a standard procedure25 using an alkyl/allyl halide to give the corresponding phenoxy
analogs 18−26 and 27−35, respectively, as shown in Scheme 2.
Derivatives 6−35 were evaluated as inhibitors of human tumor cell replication using three
human tumor cell lines, nasopharyngeal carcinoma KB, multi-drug resistant expressing p-
glycoprotein KB-VCR, and lung carcinoma A549.26, 27 Curcumin (2) and doxorubicin were
used as positive controls. The results are shown in Table 1.
Most analogs, except isoeugenol analogs 27−35, showed moderate or strong cytotoxic activity
against all three cell lines. Comparison of the corresponding dehydrozingerone (1, 6−8) and
chalcone (14−17) analogs showed that the latter compounds were more potent in each case.
Because the chalcones have a phenyl rather than methyl in the unsaturated ketone, these data
suggest that this phenyl group is important for optimal activity. Chalcone 15 showed significant
activity against the A549 cell line with an IC50 value of 0.6 μg/mL. Furthermore, the
dehydrozingerone analog 11 and chalcones 16 and 17 showed significant cytotoxic activity
against both KB (IC50 values of 2.0, 1.0, and 2.0 μg/mL, respectively) and KB-VCR (IC50
values of 1.9, 1.0, and 2.0 μg/mL, respectively) cells. The similar potencies against the parental
and drug-resistant cell lines suggested that these compounds were not substrates for the p-
glycoprotein drug efflux pump.
The substitution pattern on the benzylidene ring had some influence on potency. In particular,
among the dehydrozingerone analogs, compounds with an ortho-hydroxy group were more
active than compounds with meta- or para-hydroxy substituents [compare 6 (2′-OH, 3′-OMe),
8 (2′-OH, 4′-OMe), and 11 (2′-OH, 3′-OEt) with 1 (3′-OMe, 4′-OH), 7 (3′-OH, 4′-OMe), and
10 (3′-OEt, 4′-OH)]. Compound 12 (2′-OH, 3′-F) also exhibited significant activity, showing
that fluorine could be substituted for an alkoxy group. In addition, substitution of 3′-fluoro for
3′-hydroxy (compare 13 with 7) was beneficial.
The dehydrozingerone derivatives 18−26 showed cytotoxic activity, while the corresponding
isoeugenol derivatives 27−35 were inactive. This result supported the supposition that the
ketone on C-3 (numbering for dehydrozingerone) is important for anticancer properties.28
Phenoxydehydrozingerone analogs 18 (C-4′-prenyloxy) and 21 (C-4′-geranyloxy) showed
higher activity than dehydrozingerone itself and were as or more active than the other alkylated
compounds 19, 20, 22−26. With a longer farnesyl group, analog 22 showed decreased potency
relative to 18 and 21. This result supported those of prior investigations showing that prenylated
and/or geranylated flavonoids were more active than farnesylated compounds.17,19 Derivative
26, which has a saturated isoamyl rather than unsaturated prenyl group, showed equal and
significant activity against KB and KB-VCR cells with IC50 values of 3.6 and 3.2 μg/mL,
respectively. However, the prenylated analog (18) was about twice as potent against the drug-
resistant cell line (3.8 μg/mL, KB versus 2.0 μg/mL, KB-VCR).
In conclusion, chalcone 15 showed the highest in vitro potencies with IC50 values ranging from
0.6 to 2.4 μg/mL. The ketone at the C-3 and phenyl at the C-4 positions are necessary for
optimal cytotoxic activity. Compounds with hydroxyl at the ortho position of the benzylidene
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moiety generally showed increased activity. Among alkylated 1-analogs, alkylation of the
phenolic OH with prenyl or geranyl resulted in the highest potency.
Experimental Section
Melting points were measured with a Fisher Johns melting point apparatus without correction.
The proton nuclear magnetic resonance (1H-NMR) spectra were measured on a Varian Gemini
2000 (300 MHz) NMR spectrometer with TMS as the internal standard. All chemical shifts
are reported in ppm. Mass spectra were obtained on a TRIO 1000 mass spectrometer. Analytical
thin layer chromatography (TLC) was performed on Merck pre-coated aluminum silica gel
sheets (Kieselgel 60 F 254). Column chromatography was performed on a CombiFlash
Companion system using RediSep normal phase silica columns (ISCO, Inc., Lincoln, NE). In
case, according to the circumstances, Inc. Silica gel (200−400 mesh) from Natland (Durham,
NC) was used for column chromatography. All other chemicals were obtained from Aldrich,
Inc. unless otherwise noted.
General Procedure for Aldol Reaction12
The appropriately substituted benzaldehyde 5 was dissolved in acetone, and 1 N sodium
hydroxide was added to the solution with continuous stirring. Stirring was continued overnight.
Excess acetone was removed under reduced pressure. Upon acidification with 1 N HCl, the
reaction mixture was extracted with CHCl3 or CH2Cl2, and then solution was dried over
anhydrous Na2SO4. Solvent was removed and the yellow solid obtained was recrystallized
from EtOAc to give 6−13. Similarly, for the preparation of 14−17, benzaldehyde 5 was
dissolved in MeOH with acetophenone, and 5 N potassium hydride was added to the solution
with continuous stirring. Stirring was continued overnight. MeOH was removed under reduced
pressure. After acidification with 1 N HCl, the crude mixture was extracted with CH2Cl2, and
the solution was dried over anhydrous Na2SO4. Solvent was removed and the solid obtained
was purified with CombiFlash chromatography (EtOAc-hexane) to provide 14−17.
E-1-(2-Hydroxy-3-methoxy-phenyl)-but-1-en-3-one (6)
Starting with o-vanillin (5 g, 0.03 mol), acetone (40 mL), and 1 N NaOH (50 mL); yield 2.0 g
(30%); powder, mp 79−80 °C; 1H NMR (300 MHz, CDCl3) δ 7.84 (d, 1H, J = 16.5 Hz, 1-H),
7.12 (dd, 1H, J = 6.6, 2.7 Hz, 5'-H), 6.90−6.84 (m, 2H, 4'- and 6'-H) 6.81 (d, 1H, J = 16.5, 2-
H) 6.16 (s, 1H, OH) 3.92 (s, 3H, OCH3), 2.40 (s, 3H, 4-H); MS m/z 277 [M+Na]+
E-1-(3-Hydroxy-4-methoxy-phenyl)-but-1-en-3-one (7)
Starting with 3-hydroxy-4-methoxybenzaldehyde (1 g, 6.6 mmol), acetone (8 mL) and 1 N
NaOH (10 mL); yield 1.2 g (94%); powder, mp 96−97 °C; 1H NMR (300 MHz, CDCl3) δ 7.42
(d, 1H, J = 16.2 Hz, 1-H), 7.15 (d, 1H, J = 1.5 Hz, 2'-H), 7.06 (dd, 1H, J = 8.3, 2.1 Hz, 5'-H),
6.86 (d, 1H, J = 8.3 Hz, 6'-H), 6.59 (d, 1H, J = 16.2 Hz, 2-H), 5.70 (s, 1H, OH), 3.93 (s, 3H,
OCH3), 3.36 (s, 3H, 4-H); MS m/z 193 [M+H]+
E-1-(2-Hydroxy-4-methoxy-phenyl)-but-1-en-3-one (8)
Starting with 2-hydroxy-4-methoxybenzaldehyde (1 g, 6.6 mmol), acetone (8 mL), and 1 N
NaOH (10 mL); yield 497 mg (39%); powder, mp 129−130 °C; 1H NMR (300 MHz, CDCl3)
δ 7.78 (d, 1H, J = 16.3 Hz, 1-H), 7.34 (d, 1H, J = 8.5 Hz, 6'-H), 7.01 (d, 1H, J = 16.3 Hz, 2-
H) 6.50 (dd, 1H, J 6.48 (d, 1H, J = 2.1 Hz, 3'-H), 6.16 (s, 1H, OH) 3.82 (s, 3H, OCH3), 2.41
(s, 3H, 4-H); MS m/z 215 [M+Na]+
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Starting with benzaldehyde (500 mL, 4.9 mmol), acetone (4 mL), and 1 N NaOH (5 mL); yield
241 mg (34%); yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.58−7.53 (m, 2H, 2×Ar-H), 7.52
(d, 1H, J = 16.2 Hz, 1-H), 7.42−7.40 (m, 3H, 3×Ar-H), 6.73 (d, 1H, J = 16.2 Hz, 2-H), 2.39
(s, 3H, 4-H); MS m/z 169 [M+Na]+
E-1-(3-Ethoxy-4-hydroxy-phenyl)-but-1-en-3-one (10)
Starting with 3-ethyoxy-4-hydroxybenxaldehyde (1 g, 6.0 mmol), acetone (8 mL), and 1 N
NaOH (10 mL); yield 1.1 g (42%); needles, mp 104−105 °C; 1H NMR (300 MHz, CDCl3) δ
7.44 (d, 1H, J = 16.0 Hz, 1-H), 7.08 (br d, 1H, J = 8.4 Hz, 6'-H), 7.05 (br s, 1H, 2'-H), 6.93 (d,
1H, J = 8.4 Hz, 5'-H), 6.57 (d, 1H, J = 16.0 Hz, 2-H), 5.85 (s, 1H, OH), 4.16 (q, 2H, J = 7.0
Hz, 1'-H), 2.36 (s, 3H, 4-H), 1.48 (t, 3H, J = 7.0 Hz, 2'-H); MS m/z 229 [M+Na]+
E-1-(3-Ethoxy-2-hydroxy-phenyl)-but-1-en-3-one (11)
Starting with 3-ethyoxysalicyl-aldehyde (1 g, 6.0 mmol), acetone (8 mL), and 1 N NaOH (10
mL); yield 1.0 g (84%); powder, mp 77−78 °C; 1H NMR (300 MHz, CDCl3) δ 7.84 (d, 1H,
J = 16.5 Hz, 1-H), 7.11 (dd, 1H, J = 4.8, 2.1 Hz, 5'-H), 6.88−6.81 (m, 2H, 4'- and 6'-H) 6.21
(s, 1H, OH), 6.81 (d, 1H, J = 16.5 Hz, 2-H), 4.14 (q, 2H, J = 6.9 Hz, 1'-H), 2.40 (s, 3H, 1-H),
1.47 (t, 3H, J = 6.9 Hz, 2'-H); MS m/z 207 [M+H]+
E-1-(3-Fluoro-2-hydroxy-phenyl)-but-1-en-3-one (12)
Starting with 3-fluorosalicyl-aldehyde (200 mg, 1.4 mmol), acetone (1.6 mL), and 1 N NaOH
(2 mL); yield 239 mg (93%); prisms, mp 167−168 °C; 1H NMR (300 MHz, CDCl3) δ 7.79
(d, 1H, J = 16.5 Hz, 1-H), 7.29 (br d, 1H, J = 8.1 Hz, 6'-H), 7.12 (br t, 1H, J = 8.1 Hz, 5'-H),
6.91−6.82 (m, 2H, 4'- and 2-H), 5.96 (br s, 1H, OH), 2.41 (s, 3H, 4-H); MS m/z 203 [M
+Na]+
E-1-(3-Fluoro-4-methoxy-phenyl)-but-1-en-3-one (13)
Starting with 3-fluoro-4-methoxybenzaldehyde (500 mg, 3.24 mmol), acetone (4 mL), and 1
N NaOH (5 mL); yield 139 mg (22%); needles, mp 96−97 °C; 1H NMR (300 MHz, CDCl3) δ
7.42 (d, 1H, J = 16.2 Hz, 1-H), 7.34−7.25 (m, 2H, 2×Ar-H), 6.97 (t, 1H, J = 8.7 Hz, 5'-H), 6.59
(d, 1H, J = 16.2 Hz, 2-H), 5.85 (s, 1H, OH), 3.93 (s, 3H, OCH3), 2.37 (s, 3H, 4-H); MS m/z
217 [M+Na]+
E-1-(2-Hydroxy-3-methoxy-phenyl)-3-phenyl-propenone (15)
Starting with o-vanillin (128 mg, 0.85 mmol), acetophenone (100 μL, 0.85 mmol), MeOH (1
mL), and 5 N NaOH (1 mL); yield 80 mg (37%); powder, mp 115 °C; 1H NMR (300 MHz,
CDCl3) δ 8.05−8.02 (m, 2H, 2×Ar-H), 8.04 (d, 1H, J = 15.9 Hz, 1-H), 7.75 (d, 1H, J = 15.9
Hz, 2-H), 7.61−7.47 (m, 3H, 3×Ar-H), 7.20 (dd, 1H, J = 3.3, 2.7 Hz, Ar-H), 6.92−6.86 (m, 2H,
2×Ar-H), 6.27 (s, 1H, OH), 3.94 (s, 3H, OCH3); MS m/z 277 [M+Na]+
E-1-(3-Hydroxy-4-methoxy-phenyl)-3-phenyl-propenone (16)
Starting with 3-hydroxy-4-methoxybenzaldehyde (128 mg, 0.85 mmol), acetophenone (100
μL, 0.85 mmol), MeOH (1 mL), and 5 N NaOH (1 mL); yield 194 mg (90%); powder, 97−98
°C; 1H NMR (300 MHz, CDCl3) δ 8.04−8.00 (m, 2H, 2×Ar-H), 7.74 (d, 1H, J = 15.7 Hz, 1-
H), 7.61−7.47 (m, 3H, 3×Ar-H), 7.41 (d, 1H, J = 15.7 Hz, 2-H), 7.29 (d, 1H, J = 2.0 Hz, Ar-
H), 7.15 (dd, 1H, J = 8.2, 2.0 Hz, Ar-H), 6.88 (d, 1H, J = 8.2 Hz, Ar-H), 5.69 (br s, 1H, OH),
3.95 (s, 3H, OCH3); MS m/z 255 [M+H]+
Tatsuzaki et al. Page 4














Starting with 2-hydroxy-4-methoxybenzaldehyde (128 mg, 0.85 mmol), acetophenone (100
μL, 0.85 mmol), MeOH (1 mL), and 5 N NaOH (1 mL); yield 65 mg (30%); amorphous; 1H
NMR (300 MHz, CDCl3) δ 8.14 (d, 1H, J = 15.9 Hz, 1-H), 8.04−8.01 (m, 2H, 2×Ar-H), 7.61
(d, 1H, J = 15.9 Hz, 2-H), 7.61−7.47 (m, 4H, 4×Ar-H), 6.53 (dd, 1H, J = 8.7, 2.4 Hz, Ar-H),
6.49 (d, 1H, Ar-H), 3.82 (s, 3H, OCH3); MS m/z 277 [M+Na]+
General Procedure for Alkylation25
The mixture of dehydrozingerone (2) or isoeugenol (3), an appropriate alkyl halide, and
K2CO3 in acetone was heated to reflux overnight. The reaction mixture was evaporated under
vacuum. The crude mixture was extracted with CH2Cl2, and the organic phase was washed
with brine and dried over NaSO4 and concentrated to obtain the product as a solid. The crude
solid was purified with CombiFlash chromatography (EtOAc-hexane gradient) to obtain the
target materials (18−35).25
E-1-[3-Methoxy-4-(3-methyl-but-2-enyloxy)-phenyl]-but-1-en-3-one (18)
Starting with 1 (50 mg, 0.26 mmol), 4-bromo-2-methyl-2-butene (48 μl, 0.39 mmol), K2CO3
(252 mg, 1.82 mmol); yield 57 mg (87%); powder, mp 89−90 °C; 1H NMR (300 MHz,
CDCl3) δ 7.46 (d, 1H, J = 16.2 Hz, 1-H), 7.10 (dd, 1H, J = 8.2, 2.1 Hz, 6'-H), 7.07 (d, 1H, J =
2.1 Hz, 2'-H) 6.88 (d, 1H, J = 8.2 Hz, 5'-H), 6.60 (d, 1H, J = 16.2 Hz, 2-H), 5.51 (tt, 1H, J =
6.6, 1.2 Hz, 2”-H), 4.63 (d, 1H, J = 6.6 Hz, 1”-H), 3.90 (s, 3H, OCH3), 2.37 (s, 3H, 4-H), 1.78
(br s, 3H, CH3), 1.75 (br s, 3H, CH3); MS m/z 261 [M+H]+
E-1-(4-Allyloxy-3-methoxy-phenyl)-but-1-en-3-one (19)
Starting with 1 (100 mg, 0.52 mmol), allyl bromide (68.1 mL, 0.78 mmol), and K2CO3 (503
mg, 3.64 mmol); yield 115 mg (94%); needles, mp 71−72 °C; 1H NMR (300 MHz, CDCl3) δ
7.48 (d, 1H, J = 16.3 Hz, 1-H), 7.12−7.06 (m, 2H, 2'- and 6'-H), 6.88 (d, 1H, J = 7.8 Hz, 5'-H),
6.60 (d, 1H, J = 16.3 Hz, 2-H), 6.08 (ddt, 2H, J = 17.4, 10.5, 5.1 Hz, 2”-H) 5.42 (br d, 1H, J =
17.4 Hz, 3”-H) 5.32 (br d, 1H, J 10.5 Hz, 3”-H) 3.91 (s, 3H, OCH3), 2.37 (s, 3H, 4-H); MS m/
z 233 [M+H]+
E-1-(4-But-2-enyloxy-3-methoxy-phenyl)-but-1-en-3-one (20)
Starting with 1 (100mg, 0.52 mmol), crotyl bromide (95 μL, 0.78 mmol), and K2CO3 (503 mg,
3.64 mmol); yield 119 mg (93%); powder, mp 68−69 °C; 1H NMR (300 MHz, CDCl3) δ 7.48
(d, 1H, J = 16.2 Hz, 1-H), 7.12−7.06 (d, 2H, 2'- and 6'-H), 6.88 (d, 1H, J = 8.4 Hz, 5'-H), 6.60
(d, 1H, J = 16.2 Hz, 2-H), 5.94−5.72 (m, 2H, 2”- and 3”-H) 4.56 (d, 1H, J = 6.0 Hz, 1”-H),
3.91 (s, 3H, OCH3), 2.37 (s, 3H, 4-H), 1.75 (d, 3H, J = 5.1 Hz, 4”-H); MS m/z 247 [M+H]+
E-1-[4-(3,7-Dimethyl-octa-2,6-dienyloxy)-3-methoxy-phenyl]-but-1-en-3-one (21)
Starting with 1 (100 mg, 0.52 mmol), crotyl bromide (149 μL, 0.78 mmol), and K2CO3 (503
mg, 3.64 mmol); yield 160 mg (93%); powder, mp 56−57 °C; 1H NMR (300 MHz, CDCl3) δ
7.46 (d, 1H, J = 16.2 Hz, 1-H), 7.10 (dd, 1H, J = 8.2, 1.9 Hz, 6'-H), 7.07 (d, 1H, J = 1.9 Hz,
2'-H), 6.87 (d, 1H, J = 8.2 Hz, 5'-H), 6.60 (d, 1H, J = 16.2 Hz, 2-H), 5.51 (br t, 1H, J = 6.6 Hz,
2”-H), 5.07 (br t, 1H, J = 6.6 Hz, 6”-H), 4.67 (d, 2H, J = 6.6 Hz, 1”-H), 3.91 (s, 3H, OCH3),
2.37 (s, 3H, 4-H), 2.16−2.05 (m, 4H, 4”- and 5”-H), 0.74 (br s, 3H, CH3), 1.66 (br s, 3H,
CH3), 1.60 (br s, 3H, CH3); MS m/z 351 [M+H]+
E-1-[3-Methoxy-4-(3,7,11-trimethyl-dodeca-2,6,10-trienyloxy)-phenyl]-but-1-en-3-one (22)
Starting with 1 (100 mg, 0.52 mmol), farnesyl bromide (222.8 μL, 0.78 mmol), and K2CO3
(503 mg, 3.64 mmol); yield 182 mg (88%); powder, mp 66−67 °C; 1H NMR (300 MHz,
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CDCl3) δ 7.46 (d, 1H, J = 16.2 Hz, 1-H), 7.10 (dd, 2H, J = 7.8, 2.0 Hz, 6'-H), 7.07 (d, 1H, J =
2.0 Hz, 2'-H), 6.87 (d, 1H, J = 7.8 Hz, 5'-H), 6.60 (d, 1H, J = 16.2 Hz, 2-H), 5.51 (br t, 1H, J
= 6.0 Hz, 2”-H), 5.12−5.04 (m, 2H, 6”- and 10”-H),4.67 (d, 2H, J = 6.3Hz, 1”-H), 3.91 (s, 3H,
OCH3), 2.37 (s, 3H, 4-H), 2.18−1.92 (m, 8H, 4”-, 5”-, 8”-, and 9”-H), 0.75 (br s, 3H, 3”- or
7”-CH3), 1.68 (br s, 3H, 3”- or 7”-CH3 ), 1.59 (br s, 6H, gem-diMe); MS m/z 397 [M+H]+
E-1-(3,4-Dimethoxy-phenyl)-but-1-en-3-one (23)
Starting with 1 (100 mg, 0.52 mmol), bromomethane (50 μL, 0.78 mmol), and K2CO3 (503
mg, 3.64 mmol); yield 72 mg (78%); needles, mp 87−88 °C; 1H NMR (300 MHz, CDCl3) δ
7.47 (d, 1H, J = 16.2 Hz, 1-H), 7.13 (br d, 1H, 6'-H), 7.08 (br s, 1H, 2'-H) 6.88 (d, 1H, J = 8.2
Hz, 5'-H), 6.61 (d, 1H, J = 16.2 Hz, 2-H), 4.08 (t, 2H, J = 6.6Hz, 1”-H), 3.92 (s, 3H,
OCH3×2), 2.37 (s, 3H, 4-H); MS m/z 179 [M+H]+
E-1-(4-Ethoxy-3-methoxy-phenyl)-but-1-en-3-one (24)
Starting with 1 (100 μl, 0.65 mmol), bromoethane (59 μL, 0.97 mmol), K2CO3 (626 mg, 4.53
mmol); yield 70 mg (61%); needles, mp 108−109 °C; 1H NMR (300 MHz, CDCl3) δ 7.46 (d,
1H, J = 16.0 Hz, 1-H), 7.10 (br d, 1H, J = 8.1, 6'-H), 7.08 (br s, 1H, 2'-H) 6.87 (d, 1H, J = 8.1
Hz, 5'-H), 6.60 (d, 1H, J = 16.0 Hz, 2-H), 4.14 (q, 2H, J = 6.9 Hz, 1”-H), 3.91 (s, 3H, OCH3),
2.37 (s, 3H, 4-H), 1.48 (t, 2H, 7.0 Hz, 2”-H); MS m/z 221 [M+H]+
E-1-(3-Methoxy-4-propoxy-phenyl)-but-1-en-3-one (25)
Starting with 1 (100 mg, 0.52 mmol), 1-iodopropane (77 μL, 0.78 mmol), and K2CO3 (503
mg, 3.64 mmol); yield 57 mg (47%); needles, mp 101 °C; 1H NMR (300 MHz, CDCl3) δ 7.46
(d, 1H, J = 16.2 Hz, 1-H), 7.10 (br d, 1H, 6'-H), 7.08 (br s, 1H, 2'-H) 6.87 (d, 1H, J = 8.0 Hz,
5'-H), 6.60 (d, 1H, J = 16.1 Hz, 2-H), 4.02 (t, 2H, J = 6.9 Hz, 1”-H), 3.90 (s, 3H, OCH3), 2.37
(s, 3H, 4-H), 1.89 (qt, 2H, J = 7.3, 6.9 Hz, 2”-H), 1.05 (t, 3H, J = 7.3 Hz, 3”-H); MS m/z 207
[M+H]+
E-1-[3-Methoxy-4-(3-methyl-butoxy)-phenyl]-but-1-en-3-one (26)
Starting with 1 (100 mg, 0.52 mmol), 1-methyl-3-bromobutane (102.3 μL, 0.78 mmol), and
K2CO3 (503 mg, 3.64 mmol); yield 32 mg (23%); needles, mp 77−78 °C; 1H NMR (300 MHz,
CDCl3) δ 7.45 (d, 1H, J = 16.1 Hz, 1-H), 7.10 (br d, 1H, J = 8.4 Hz, 6'-H), 7.07 (br s, 1H, 2'-
H) 6.88 (d, 1H, J = 8.4 Hz, 5'-H), 6.60 (d, 1H, J = 16.1 Hz, 2-H), 4.08 (t, 2H, J = 6.6 Hz, 1”-
H), 3.90 (s, 3H, OCH3), 2.37 (s, 3H, 4-H), 1.92−1.70 (m, 1H, 3”-H), 1.77 (br t, 2H, J = 6.6 Hz,
2”-H), 0.98 (br s, 3H, CH3), 0.96 (br s, 3H, CH3); MS m/z 263 [M+H]+
2-Methoxy-1-(3-methyl-but-2-enyloxy)-4-propenyl-benzene (27)
Starting with 3 (100 μl, 0.65 mmol), 4-bromo-2-methyl-2-butene (118 μL, 0.97 mmol),
K2CO3 (626 mg, 4.53 mmol); yield 45 mg (30%); yellow oil; 1H NMR (300 MHz, CDCl3) δ
6.89−6.78 (m, 3H, 3-, 5-, and 6-H), 6.33 (d, 1H, J = 15.6 Hz, 1”-H) 6.16−6.04 (m, 1H, 2”-H),
5.89−5.71 (m, 2H, 2'- and 3'-H), 4.50 (d, 2H, J = 5.4 Hz, 1'-H), 3.87 (s, 3H, OCH3), 1.86 (d,
3H, J = 6.3 Hz, 3”-H), 1.76 (s, 3H, CH3), 1.72 (s, 3H, CH3); MS m/z 233 [M+H]+, 255 [M
+Na]+
1-Allyloxy-2-methoxy-4-propenyl-benzene (28)
Starting with 3 (100 μl, 0.65 mmol), allyl bromide (85 μL, 0.97 mmol), K2CO3 (626 mg, 4.53
mmol); yield 78 mg (59%); pale yellow oil; 1H NMR (300 MHz, CDCl3) δ 6.89−6.78 (m, 3H,
3-, 5-, and 6-H), 6.33 (d, 1H, J = 16.2 Hz, 1”-H) 6.16−6.02 (m, 1H, 2”-H), 5.42 (br d, 1H, J =
17.4 Hz, 3'-H), 5.27 (br d, 1H, J = 9.6 Hz, 3'-H), 4.60 (d, 2H, J = 5.7 Hz, 1'-H), 3.88 (s, 3H,
OCH3), 1.86 (d, 3H, J = 6.3 Hz, 3”-H); MS m/z 205 [M+H]+
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Starting with 3 (100 μl, 0.65 mmol), crotyl bromide (118 μL, 0.97 mmol), K2CO3 (626 mg,
4.53 mmol); yield 98 mg (69%); pale yellow oil; 1H NMR (300 MHz, CDCl3) δ 6.89−6.78
(m, 3H, 3-, 5-, and 6-H), 6.33 (d, 1H, J = 15.3 Hz, 1”-H) 6.16−6.04 (m, 1H, 2”-H), 5.51 (m,
1H, 2'-H), 4.55 (d, 2H, J = 6.6 Hz, 1'-H), 3.87 (s, 3H, OCH3), 1.86 (d, 3H, J = 6.3 Hz, 3”-H),
1.71 (d, 3H, J = 5.1 Hz, 4'-H); MS m/z 219 [M+H]+
2-Methoxy-4-propenyl-1-(3,7,11-trimethyl-dodeca-2,6,10-trienyloxy)-benzene (30)
Starting with 3 (100 μl, 0.65 mmol), farnesyl bromide (277 μL, 0.78 mmol), and K2CO3 (626
mg, 4.53 mmol); yield 215 mg (90%); yellow oil; 1H NMR (300 MHz, CDCl3) δ 6.88−6.78
(m, 3H, 3-, 5-, and 6-H), 6.33 (d, 1H, J = 15.3 Hz, 1”-H) 6.16−6.04 (m, 1H, 2”-H), 5.51 (m,
1H, 2'-H), 5.10 (m, 2H, 6'- and 10'-H), 4.60 (d, 2H, J = 6.3 Hz, 1'-H), 3.87 (s, 3H, OCH3), 2.15
−1.90 (m, 8H, 4'-, 5'-, 8'-, 9'-H) 1.86 (d, 3H, J = 6.3 Hz, 3”-H), 1.77 (s, 3H, CH3), 1.72 (s, 3H,
CH3) 1.59 (s, 6H, gem-diCH3); MS m/z 369 [M+H]+
1,2-Dimethoxy-4-propenyl-benzene (32)
Starting with 3 (100 μl, 0.65 mmol), bromomethane (61 μL, 0.97 mmol), K2CO3 (626 mg, 4.53
mmol); yield 101 mg (88%); pale yellow oil; 1H NMR (300 MHz, CDCl3) δ 6.89−6.78 (m,
3H, 3-, 5-, and 6-H), 6.34 (d, 1H, J = 15.9 Hz, 1”-H) 6.16−6.04 (m, 1H, 2”-H), 3.89 (s, 3H,
OCH3), 3.87 (s, 3H, OCH3)1.87 (d, 3H, J = 6.3 Hz, 3”-H); MS m/z 179 [M+H]+
2-Methoxy-4-propenyl-1-propoxy-benzene (34)
Starting with 3 (100 μl, 0.65 mmol), 1-iodopropane (96 μL, 0.97 mmol), K2CO3 (626 mg, 4.53
mmol); yield 129 mg (96%); pale yellow oil; 1H NMR (300 MHz, CDCl3) δ 6.89−6.80 (m,
3H, 3-, 5-, and 6-H), 6.33 (d, 1H, J = 1.56 Hz, 1”-H) 6.15−6.04 (m, 1H, 2”-H), 3.96 (t, 3H, J
= 6.7 Hz, 1'-H), 3.87 (s, 3H, OCH3) 1.91−1.79 (m, 5H, 3”- and 2'-H), 1.03 (t, 3H, J = 7.5 Hz,
3'-H); MS m/z 235 [M+H]+
2-Methoxy-1-(3-methyl-butoxy)-4-propenyl-benzene (35)
Starting with 3 (100 μl, 0.65 mmol), 1-methyl-3-bromobutane (127 μL, 0.97 mmol), K2CO3
(626 mg, 4.53 mmol); yield 91 mg (59%); pale yellow oil; 1H NMR (300 MHz, CDCl3) δ 6.89
−6.78 (m, 3H, 3-, 5-, and 6-H), 6.33 (d, 1H, J = 15.9 Hz, 1”-H) 6.16−6.04 (m, 1H, 2”-H), 4.03
(t, 2H, J = 6.9 Hz, 1'-H), 3.87 (s, 3H, OCH3), 1.86 (d, 3H, J = 6.6 Hz, 3”-H), 1.92−1.70 (m,
3H, 2'- and 3'-H), 0.97 (s, 3H, CH3), 0.95 (s, 3H, CH3); MS m/z 263 [M+H]+
Cytotoxic Activity Assay
The in vitro cytotoxicity assay was carried out according to procedures described in Rubinstein
et al.26 Drug stock solutions were prepared in DMSO, and the final solvent concentration was
<1% DMSO (v/v), a concentration without effect on cell replication. The human tumor cell
line panel consisted of epidermoid carcinoma of the nasopharynx (KB), lung carcinoma
(A-549). The drug resistant cell line was KB-VCR, an MDR variant selected for growth in
vincristine. It is cross-resistant to doxorubicin (Table 1). Detailed characterization of this cell
line is described elsewhere.27 Cells were cultured at 37 °C in RPMI-1640 with 100 μg/mL
kanamycin and 10% (v/v) fetal bovine serum in a humidified atmosphere containing 5%
CO2. Initial seeding densities varied among the cell lines to ensure a final absorbance of 1−2.5
A562 units. Drug exposure was for 2 days and the IC50 value, the drug concentration that
reduced the absorbance by 50%, was interpolated from dose-response data. Each test was
performed in duplicate, and absorbance readings varied no more than 5% between replicates.
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Structures of Dehydrozingerone (1), Curcumin (2), Isoeugenol (3) & 2-Hydroxychalcone (4).
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Syntheses of Dehydrozingerone (6−13) and Chalcone (14−17) Analogs
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C-4' Alkylated Dehydrozingerone (18−26) and Isoeugenol (27−35) Analogs
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1 >10 >10 >10
6 3.8 2.0 2.5
7 10.0 8.2 >10
8 3.8 4.0 3.5
9 5.3 5.6 2.8
10 7.7 7.8 8.5
11 2.0 1.9 2.3
12 2.1 3.0 3.0
13 4.3 5.0 5.5
Chalcone Analogs
14 3.5 1.9 2.3
15 2.4 1.3 0.6
16 1.0 1.0 3.5
17 2.0 2.0 3.8
C-4′ Alkylated Dehydrozingerone Analogs
18 5.7 3.5 3.8
19 6.8 5.0 5.8
20 4.8 3.4 6.8
21 2.2 3.3 3.4
22 6.5 7.4 7.4
23 8.6 7.8 8.0
24 5.5 8.0 >10
25 6.5 4.2 5.8
26 3.6 3.2 7.2
C-4′ Alkylated Isoeugenol Analogs
27−35c >10 >10 NDd
Controls
Curcumin (2) 5.5 3.1 5.2
Doxorubicin 0.1 2.7 0.1
a
Cytotoxicity as IC50 values for each cell line, the concentration of compound that caused 50% reduction in absorbance at 562 nm relative to untreated
cells using the sulforhodamine B assay. The average value is from two independent determinations and variation (SEM) was no greater than 10%.
b
Human epidermoid carcinoma of the nasopharynx (KB), multi-drug resistant expression P-glycoprotein (KB-VCR), human lung carcinoma (A549).
c
30 and 33 were not tested.
d
ND = Not determined.
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